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Law, Ethics, Religion, and Clinical Translation in the 21st Century—
A Discussion with Andrew Webster
About Professor Andrew Webster
Professor Webster received his B.Sc. in Social Sciences in
1974 at the Polytechnic of the South Bank, then earned his
Ph.D. in the Sociology of Science at the University of York
in 1981. He is currently Professor in the Sociology of Science
and Technology, Director of the Science and Technology
Studies Unit (SATSU), and Academic Coordinator for the
Social Sciences at the University of York.
From 2005 to 2009 Professor Webster was the Coordina-
tor of the International Stem Cell Initiative (SCI), and is cur-
rently the Coordinator of the Regenerative Medicine in
Europe (REMEDiE) project as well as a member of the Medi-
cal Research Council’s UK Stem Cell Bank Steering Commit-
tee, the Medical Research Council’s Medical Ethics Commit-
tee, the UK National Stem Cell Network Committee.
Dr. Webster sits on the editorial board of the journals
Health Informatics, New Genetics and Society, and Industry
and Higher Education. He was elected a Fellow of the Acad-
emy of Social Sciences in 2007.
‘‘As a Sociologist, I Have Always Been Interested In The
Social, Cultural, And Economic Factors That Shape
Health Innovation...’’
‘‘The development of new health technologies has long been
a focus of my research since completing my doctorate at
York almost 30 years ago. As a sociologist, I have always
been interested in the social, cultural, and economic factors
that shape health innovation, especially in respect to new
developments in the biosciences (my earliest work was on the
radical changes brought about by molecular biology in the
mid-1980s). My work has shown how new health technolo-
gies and the techniques, models, and assumptions on which
they are based are tied into other technologies, practices, and
social relations and how their adoption depends on the way
these processes work together. This is true whether they
appear in the most mundane (such as the stethoscope) or the
most advanced (say the magnetic resonance imaging scanner
or human embryonic stem cells [hESCs]) of forms. This has
important implications for the perceived utility and so transla-
tion of innovation into practice.’’
‘‘Over the past 10 years, I have directed two major
research programs exploring these issues, the Innovative
Health Technologies program and the Stem Cell Initiative,
funded by the two research councils, the Economic and Social
Research Council (ESRC) and the Medical Research Council
(MRC). The ﬁrst covered a wide range of innovation, includ-
ing pharmaceuticals, new devices, and ehealth, while the
more recent has been exclusively devoted to stem cells devel-
opment in the UK and more globally.’’
‘‘My Work at York Has Focused on
Standardization of hESCs’’
‘‘The standardization process has been marked by a gradual
stabilization of some biological markers for hESCs, but these
have not proved deﬁnitive in terms of ‘stemness’ and so ‘plu-
ripotency,’ nor predictive of patterns of differentiation into
speciﬁc cell lines. We have found that the problem of deter-
mining pluripotency has led to a growing pragmatism in the
hESC network to continue to produce what are seen as pro-
ductive results, effectively a shift from a search for ‘essential’
to ‘functional’ attributes of hESCs. Standardization has
become to be seen as meaningful and so useful through a
focus on ‘how’ rather than ‘why’ lines do what they do. This
suggests hESCs are less ‘pluri’ but (ironically thereby) more
‘potent’. Standardization is of course double-edged inasmuch
as it can also impose a method on the community that may
drive science toward early, suboptimal models of biological
markers. Moreover, even if this were not an issue, the goal to
create general reference standards across laboratories is difﬁ-
cult to achieve because it is often the case that the way cells
work in laboratories differs when they go into good manufac-
turing practice (GMP) ‘clean rooms.’ We have also examined
how standardization relates to the automation of cell cultures
and scale-up, and have argued that in respect to the latter
there’s an important role to be played in the near future, prob-
ably by a public sector or not-for-proﬁt body, doing some of
the basic spadework, especially in regard to puriﬁcation and
scale-up, for the wider community.’’
‘‘These particular interests we have in the ﬁeld reﬂects
one of the core themes of the Science and Technology Studies
Unit (SATSU) at York, that is, the sociology of the bioscien-
ces. Our work has examined not only developments in regen-
erative medicine (RM) but also the development of pharmaco-
genetics, bioinformatics, and cord blood banking. The unit
also focuses on two other research themes: the regulation of
new science and technology and the role of the digital world
in shaping social life more generally.’’
‘‘Many Sociologists Work Closely, As I Have Done, With
Stem Cell Scientists And Clinicians On Shared Concerns
And Interests’’
‘‘For example, I have been involved in collaborative work
with the Centre for Stem Cells Biology on how standards
have been developed internationally across the hESC commu-
nity and the technical and transorganizational issues that have
had to be addressed. Another collaboration with colleagues at
York has explored the innovation paths that are more, or less,
successful in respect to hematopoietic cell lines. The SCI pro-
vided an excellent opportunity to explore the social, cultural,
regulatory, and economic factors that shape the development
of RM, enabling a strongly comparative analysis involving
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clear from the ﬁndings that the status and role of RM varies
hugely across countries and this is only partly linked to politi-
cal or religious beliefs. Much also depends on the more im-
portant relationship between research and clinical systems and
the role and relative impact of international and local regula-
tory agencies. In Japan, for example, there is a very strong
clinical push in tissue engineering that depends on the govern-
ment promoting tight relations between hospital clinicians and
researchers (with little room for corporate activity).’’
‘‘...There Is a Need To Deﬁne What The Quality Control
Requirements Of Large-Scale Cell Culture Are Likely to
be Before The Move Toward Securing Clinical Grade
Lines Is Made’’
‘‘My role as Coordinator in the SCI began in November 2005
and ran through to June 30, 2009. The ESRC has provided £3
million to support a range of activities that would build
research capacity and raise awareness within the UK social
science community in regard to the emerging ﬁeld. The SCI
network has now grown to some 45 UK-based researchers
who have focused on a number of discrete areas, such as the
development of standards in the ﬁeld (crucial to its longer
term success), the pattern of capital investment and return it
has, the clinical and ethical questions it raises, and what new
issues it poses for those charged with regulating an ever-
changing and at the same time uncertain ‘promise’ of product
development and clinical therapy. The SCI membership has
been drawn on by a wide range of stakeholders, especially
within the policy and bioscience arenas, to provide advice
and input to a wide range of debates and speciﬁc policy ques-
tions, such as the development of the HFEA Bill in 2007–
2008, the work of the UK Stem Cell Bank, the Stem Cell
Dialogue project run by the MRC and BBSRC, close coopera-
tion with the UK National Stem Cell Network, and wide
engagement with divergent publics within the different
regions across the UK, both during and beyond the annual
‘Science Weeks.’’’
‘‘The REMEDiE project, that I coordinate, examines the
current European engagement with RM and how this com-
pares with that found more globally. Its primary objective is
to understand how the political, economic, and bioethical
developments within the ﬁeld operate at national and transna-
tional levels and shape the future clinical and corporate activ-
ity within RM. The various Work packages focus on different
aspects of these three areas and undertake comparative empir-
ical analyses within and beyond Europe. The overall objective
is to determine how the project ﬁndings can contribute toward
European Community Member State and European Parliamen-
tary policy-making in this area. In regard to the latter, the
Consortium has liaised with the Scientiﬁc Technology
Options Assessment group, the European Parliamentary
Agency that advises on future technology options, and is pro-
viding information about the results of our work this coming
November. We have also linked up with the European
Patients Foundation to provide results through their Newslet-
ter. Some of the current work we are doing is showing that in
regard to the RM science base, Germany and the UK have
the stronger national research capacities in the ﬁeld (the latter
with notably strong links across the social and biosciences)
and have the potential to move more quickly in this area in
terms of innovation, effective regulation, and clinical delivery.
Germany is also particularly well placed in regard to the ﬁ-
nancial stability of its RM investment proﬁle compared with
other Member States.’’
‘‘On the question of clinical translation two key points are
emerging: the prospective take-up of new products will
depend on ﬁrms addressing more effectively matters of clini-
cal utility and relevance against existing therapies or products,
if they are to persuade end users of the relative merits of RM.
Second, there is a need to deﬁne what the quality control
requirements of large-scale cell culture are likely to be before
the move toward securing clinical grade lines is made. This
will require dialogue between regulators, stem cell banks
(such as those in the UK and Spain), clinical research labora-
tories and companies.’’
‘‘What Is Important Is How The Regulatory
Environment Approaches The Variability of
Any Lines as They Are Scaled Up...’’
‘‘The most recent developments in RM are often said to be
associated with the arrival of induced pluripotent (iPS) cells.
Although these short-circuit much of the ethical debate of
hESC-derived lines, and have led to a huge increase in big
Pharma interest, the stability of such lines in terms of thera-
peutic development is as tricky an issue as it is for hESCs.
How much biological variability can be accommodated while
GMP variability is not? Another key issue relates to the ways
in which current clinical trials in the ﬁeld are working to
police and manage it effectively and whether any changes in
trial protocols because of the problems of working with bio-
logically live tissue are needed. Both these issues raise ques-
tions about the sort of longer term equivalent of pharmacovi-
gilance that will be needed to optimize patient safety in the
RM ﬁeld.’’
‘‘There is a lack of an internationally uniﬁed regulatory
framework for stem cell and tissue transplantation (which cre-
ates various problems such as the proper management of the
transfer of hESC lines between different regulatory jurisdic-
tions). Problems with inconsistent tissue banking procedures,
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1916 Interview Seriesinconsistent donor consent, uncertain efﬁcacy and discordant
regulatory standards make things especially problematic.’’
‘‘Trust In Science Is a Recurring Theme In This Research,
for Both Scientists and the Public’’
‘‘In general, public opinion has been broadly very favorably
disposed to stem cell research as the Stem Cell Dialogue
report found. Extensive work by one of the SCI teams (Sarah
Parry and her colleagues at the University of Edinburgh) on
public attitudes to stem cell science shows that most people
did not object to the use of human material such as cord
blood, embryos, or fetal tissue, even if they might express
some discomfort about this. An important intermediary
agency in helping to reassure public opinion has been the UK
Stem Cell Bank which plays a pivotal role as a public-good
agency in helping to ensure that the sourcing and management
of cell lines is conducted according to a high ethical
standard.’’
‘‘Much of the Stem Cell Dialogue was about the conven-
tional approach that says we need a better public understand-
ing of science. Although this is always to be fostered, it has
long been demonstrated that more understanding does not
thereby yield more (unquestioning) support for the ﬁeld.
Rather it leads to a more nuanced and perhaps critical view.
Rather than seeing this as a problem, it would be much better
to be more ready to acknowledge the provisionality of the sci-
ence and thereby the prospects for therapy. It would be much
better to engage with the public in terms of a ‘public under-
standing of scientiﬁc practice’ which would seek to show the
challenges that are faced on the ground. This would provide
for a more informed engagement with science and between
science and the diverse publics ‘out there.’ It would also help
to avoid the litigious nature of the US stem cell policy pro-
cess which most recently has seen a judicial ruling bringing a
halt to Federal funding of hESC research. Even so, govern-
ment and the science community need to be clear about where
they see the line being drawn with respect to actual public
engagement in wider governance processes.’’
‘‘The Eventual Business Model for the New
Generation of RMs Based On Either iPS or
hESC-Derived Therapies Will Crucially Depend
on the Practical Context In Which The Technology
Can Be Used’’
‘‘This business model is very likely to be much more limited
than some of the hype one reads, and more likely to involve
application in surgical settings rather than as a therapy akin to
a mass drug market. On the other hand, what we are seeing in
China may break the mold through structuring hospital/
research laboratories relations much more tightly together,
allowing for a wider adoption of RM there. In the U.S. and
Europe, much will also depend on companies ensuring fol-
low-up for patients after delivery of their products. For exam-
ple, Apligraf was only successful after the speciﬁcation for
the product was changed in response to patient/carer feed-
back. This highlights the importance of clinical context. Two
things need to be understood here: ﬁrst, clinical relevance,
what would make something worthwhile having? Second,
clinical practice, what organizational and cultural factors
determine this?’’
‘‘Over the next 10 years or so there will be some key
issues that will need to be followed. These include the iPS/
hESC relationship and how this will play out in not merely a
technical sense (determining pluripotency for example) but a
regulatory one too (in respect to future trials and questions of
safety). In regard to trialing itself, the outcome of both the
UK ReNeuron and US Geron trials will be especially impor-
tant. Clearly, it is in Geron’s interests that their trial is clini-
cally successful to ensure their stock, both in its reputational
and capital forms, remains high so the trial will be kept under
extremely close review, by those in and outside of the com-
pany. The commercial impact of the Geron trial results is also
hugely signiﬁcant. If the patients begin to regain sensation but
then lose it as the body’s immune system kicks in, will that
be regarded as a success or failure? The current volatility of
the international market will in part determine how this is
answered.’’
‘‘Overall, we need to learn that the movement into thera-
pies based on live biologics poses new challenges for all con-
cerned, and will require a quite explicit but thereby legitimate
embrace of uncertainty. In a time of recession and public ex-
penditure cuts, it is ironic that the role of public sector
research will become increasingly important and play a key
role in early stage clinical development. This is because trans-
lational research should be seen as a complex two-way ﬂow
of knowledge between bench and bedside, not from bench to
bedside, as is the usual mantra.’’
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